Paul Edward Larkin’s Post

Thrilled to announce my first publication! Read our research paper titled “Clinical Outcomes of Transjugular Intrahepatic Portosystemic Shunt Among Cirrhosis Patients With Recurrent Esophageal Variceal Bleeding”. #FirstPublication #Research #AcademicAchievement

Complement activation and effector pathways in membranous nephropathy

“The scientific status and future of the therapies in Anthroposophic Medicine” Where do we stand? What are the barriers and opportunities for the further development and implementation of the therapies in anthroposophic medicine (AM) and for AM therapy research? How do we connect to current developments? What must and can we do in the next 10 years? An AM research congress on evidence, relevant developments in AM, conventional medicine and Traditional, Complementary & Integrative Healthcare (TCIH), research communities and research agendas development for the future. Programm und Anmeldung: https://lnkd.in/eEqCn9Qr

Support critical PMD research! The Natural History Study aims to understand the progression of Pelizaeus-Merzbacher Disease (PMD) using medical records and biological samples. With new therapeutic approaches on the horizon, there's an urgent need for this data to design effective clinical trials. Let's advance PMD research and pave the way for future treatments. Learn more and contribute to the study: https://lnkd.in/gbKVcgRa

Neurofeedback: Groundbreaking therapy or expensive placebo? The scientific community remains divided on neurofeedback. While some studies showcase its potential, others compare its effects to those of a placebo. Given its high costs and the time commitment it demands, it's crucial for healthcare professionals and patients to critically assess its value and effectiveness. Let's delve into the latest research and explore the real-world applications of neurofeedback🧠💬 https://lnkd.in/giKmT4yw

Excited to share our latest publication in a PUBMED indexed journal, titled "True Brachial Artery Aneurysm: A Systematic Review". One of my new years resolution was to publish impactful research. Something that adds value to the existing literature. Our systematic review delves into the demographic characteristics, aetiologies, clinical manifestations, and various treatment methods of true brachial artery aneurysms. This is basically a systematic review of case reports as you can see from the results that of 113 articles, 100 (88.4%) were case reports. True brachial artery aneurysm, although a rarity, may lead to significant neurological and vascular problems if ignored. We also identified arteriovenous fistula and immunosuppression as two significant risk factors in the development of true brachial artery aneurysm. Thus, this paper provides intriguing clinical information and lays the foundation for larger multicentric studies. Collaborating with an incredible team - Syed Muhammad Aalam, Saima Moin, Rabia Gilani, Nida Jawad, and Aayat Ellahi - has been a highlight of this project. Full text: https://lnkd.in/efJU-J6A #medicalresearch #systematicreview #hardwork #selflearning #scientificpublication #healthcareinnovations

🚨📢 Check out the latest publication from my #BantingCanada fellowship, out today in JAMA Internal Medicine! Here, Drs. Ronda Lun, Michael Hill and I discuss the limitations/biases in retrospective data on safety of thrombolytics for #IschemicStroke in patients taking #DirectOralAnticoagulants. We are in dire need of prospective/randomized evidence to inform treatment decisions in this clinical setting. 🧠 https://lnkd.in/g6r_AY4S

Randomized controlled trials are considered the gold standard in regulatory decision making, as observational studies are known to have important methodological limitations. However, real-world evidence (#RWE) may be helpful in specific situations.   Recently, PhD student Stefan Verweij and his colleagues, observed that for multiple sclerosis, real-world studies yielded treatment effect #estimates similar to those obtained from randomized controlled trials (#RCT’s). They compared evidence obtained from tens of published RCTs with evidence obtained from observational studies in a comprehensive systematic review and network meta analysis (#NMA), using posterior predictive distributions. The authors argue that, in regulatory decision making, observational studies may supplement pivotal randomized controlled trials in relapsing–remitting multiple sclerosis. For instance, by facilitating the extrapolation of trial results to the broader patient population. ➡ Do you want to learn more about this study? Read the open access article here: https://lnkd.in/ek9ZWsft #RegulatoryScience #MS Wouter Ahmed, Guiling Zhou, Dimitris Mavridis, Stavros Nikolakopoulos, Katrien Oude Rengerink, Maarten J. Bijlsma, Peter Mol, Prof. dr. Eelko Hak.

A research team from the McGill University is seeking participants for a study that aims to co-create the first comprehensive definition of pain-related suffering shaped directly by people living with pain. This study is part of a line of research which aims to inform the development of clinical interventions that help recognize and alleviate suffering among people living with pain. ➡️Visit https://lnkd.in/gCgpt7rx to participate

Not quite beach reading but some quick reads below that discuss some of the challenges in finding the biospecimens needed for research. Topic you are interesting in learning more about in sample procurement, send me a message.